Mantle Cell Lymphoma · line 2 · Acalabrutinib monotherapy (continuous, ACE-LY-004) — r/r MCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ACALABRUTINIB-MCL |
| ID | IND-MCL-2L-ACALABRUTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L+ preferred BTKi for r/r MCL. Better cardiac safety vs ibrutinib is dominant advantage. Funding gap (NSZU does not reimburse acalabrutinib) — ibrutinib practical fallback.
Used By
Algorithms
ALGO-MCL-2L- ALGO-MCL-2L